Related Experiment Video
Updated: Jul 20, 2026

Orthotopic Rat Kidney Transplantation: A Novel and Simplified Surgical Approach
Published on: May 7, 2019
Immunoglobulin therapy for plasma cell-rich rejection in the renal allograft
Horacio E Adrogue1, Liliana Soltero, Geoffrey A Land
1Nephrology Section, Baylor College of Medicine, The Methodist Hospital, Houston, TX, USA. horacioa@bcm.edu
Abstract:
Plasma cell-rich acute rejection (PCAR) is associated with poor allograft outcome in renal transplantation. Previous studies report a graft half-life of six months after a single PCAR episode. However, the management of this condition is unclear. Intravenous immunoglobulin (IVIG) therapy, by virtue of its immunomodulating properties, and its influence on B-cell maturation into plasma cells, may be a good candidate for reversing this type of rejection. We report four episodes of PCAR in two patients who responded well to IVIG with improvement in renal function.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Kidney Transplant I: Introduction
Cell-mediated Immune Responses
Chronic Kidney Disease III: Interprofessional Care